- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02569450
Evaluation of Control Chart Impact on Surgical Outcomes (SHEWHART)
March 2, 2022 updated by: Hospices Civils de Lyon
The Impact of Surgical Outcomes Monitoring Using Control Chart on Surgical Performance: A Cluster Randomized Trial
This two arms parallel cluster-randomized trial will evaluate the impact of monitoring surgical outcomes using Shewhart control chart (intervention) on the occurence of major adverse events, among a large sample of French surgical departments.
Trends in surgical outcomes before and after the intervention will be compared between arms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
157594
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lyon, France, 69003
- Hospices Civils de Lyon, Pôle IMER
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All patients operated in participating French public and private hospitals (cluster)
Description
Inclusion Criteria:
- All adults needing a digestive surgery who are hospitalized in one of the 40 departments
Exclusion Criteria:
- Age < 18 years old
- Hospitalization <24 hours
- Absence of surgical procedure
- Ambulatory care
- Palliative care
- Organ transplantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Intervention arm
Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
|
|
|
Hospitals in control arm
Hospitals randomly assigned to the control arm without surgical outcome monitoring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of any major adverse event during hospitalization
Time Frame: within 30 days following surgical procedure
|
Major adverse events include postoperative death, complication, unplanned intensive care stay or reoperation within 30 days of surgery.
|
within 30 days following surgical procedure
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of any death during hospitalization within 30 days of surgery
Time Frame: within 30 days following surgical procedure
|
within 30 days following surgical procedure
|
|
Occurrence of any complication during hospitalization within 30 days of surgery
Time Frame: at the end of hospitalization
|
at the end of hospitalization
|
|
Occurrence of unplanned intensive care stay during hospitalization within 30 days of surgery
Time Frame: within 30 days following surgical procedure
|
within 30 days following surgical procedure
|
|
Occurrence of reoperation during hospitalization within 30 days of surgery
Time Frame: within 30 days following surgical procedure
|
within 30 days following surgical procedure
|
|
Number of hospital bed-days consumed
Time Frame: within 30 days following surgical procedure
|
within 30 days following surgical procedure
|
|
Hospitalization costs from a health insurance perspective
Time Frame: within 30 days following surgical procedure
|
within 30 days following surgical procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
December 31, 2018
Study Registration Dates
First Submitted
October 5, 2015
First Submitted That Met QC Criteria
October 5, 2015
First Posted (Estimate)
October 6, 2015
Study Record Updates
Last Update Posted (Actual)
March 17, 2022
Last Update Submitted That Met QC Criteria
March 2, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 69HCL14_0282
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive Surgery
-
Centre Hospitalier Universitaire DijonCompletedUrinary Surgery | Digestive SurgeryFrance
-
IHU StrasbourgRhythm Diagnostic SystemsCompleted
-
Gérond'ifRecruitingDigestive and Urological SurgeryFrance
-
Groupe Hospitalier Paris Saint JosephCompletedEndoscopy | Surgery, Digestive SystemFrance
-
GCS Ramsay Santé pour l'Enseignement et la RechercheEuraxi PharmaNot yet recruitingSurgery | Digestive System DiseaseFrance
-
Centre Hospitalier Universitaire DijonActive, not recruitingElective Surgery for Any Digestive CancerFrance
-
Stanford UniversityTauTona GroupCompletedLaparoscopic SurgeryUnited States
-
Institutul Clinic FundeniCompleted
-
Istanbul UniversityCompletedLaparoscopic SurgeryTurkey
-
University Hospital, GrenobleCompletedColorectal SurgeryFrance
Clinical Trials on Surgical outcomes monitoring using Shewhart control chart
-
Kutahya Health Sciences UniversityCompletedImpacted Third Molar Tooth | Trigemino-Cardiac ReflexTurkey
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of California... and other collaboratorsEnrolling by invitationHeart Diseases | Cardiovascular Diseases | Coronary Artery Disease | Stroke | Sleep Disorder | Insomnia | Sleep Disturbance | Metabolic Disease | Autonomic Dysfunction | Insomnia Chronic | Systemic Inflammatory Response | Insomnia, PrimaryUnited States
-
The City College of New YorkNational Institute on Drug Abuse (NIDA); Medical University of South CarolinaCompletedSubstance-Related Disorders | Stress Disorders, Post-TraumaticUnited States
-
Charles University, Czech RepublicCompletedHyperglycemia | Cardiac SurgeryCzech Republic
-
Johns Hopkins UniversityMercy Medical CenterCompletedDelirium | Lumbar Radiculopathy | Lumbar Osteoarthritis | Lumbar Spine Disc DegenerationUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumRecruitingLymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCNUnited States, Australia
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI)RecruitingMedulloblastomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative Neoplasm | Acute Leukemia of Ambiguous Lineage | Acute Undifferentiated Leukemia | Mast Cell Leukemia | Acute Biphenotypic Leukemia | Chronic Monocytic Leukemia | Myelodysplastic... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte CorporationCompletedPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
National Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell LymphomaUnited States